Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label bevacizumab + paclitaxel + gemcitabine first-line study in HER2-negative advanced breast cancer
2008-003657-32Phase 2Completed
- Sponsor
- Roche
- Start
- Oct 2008
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab, paclitaxel and gemcitabine in breast cancer, sponsored by Roche. Primary endpoints: Progression-free survival and Safety. Started Oct 2008; status: completed.
02
Drugs
bevacizumabpaclitaxelgemcitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2008-003657-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003657-32.